-
[show abstract]
[hide abstract]
ABSTRACT: A 70-year-old man was diagnosed as thyroid medullary carcinoma with multiple bone metastases. He underwent total thyroidectomy and cervical lymph node dissection. After one year, the pain from his bone lesions was becoming severe. To relieve the pain, he was administered opioids and external-beam radiation therapy. However, he continued to have substantial multiple bone pain. We used combination therapy of strontium-89 chloride for the treatment of widespread multiple bone pain and external-beam radiation therapy for localized pain. That combination therapy was effective and improved the QOL of the patient. We used strontium-89 chloride four times within one year, and no serious side effects occurred during therapy. Our thoroughly investigated case suggests that strontium-89 therapy is one of the effective and safe therapies for patients with painful bone metastases of thyroid medullary carcinoma.
Gan to kagaku ryoho. Cancer & chemotherapy 06/2012; 39(6):951-3.
-
[show abstract]
[hide abstract]
ABSTRACT: A 49-year-old pre-menopausal woman was diagnosed with left breast cancer(T2N0M0, stage II A). She was also diagnosed with chronic renal failure for the first time. We performed left breast conserving surgery and sentinel lymph node biopsy. Afterwards, we administered TC therapy(docetaxel 75mg/m / 2, cyclophosphamide 250 mg/m2)as adjuvant therapy every four weeks. No serious side effects occurred during therapy. TC therapy was a safe regimen for a patient with chronic renal failure in our case.
Gan to kagaku ryoho. Cancer & chemotherapy 02/2012; 39(2):265-7.
-
[show abstract]
[hide abstract]
ABSTRACT: A 91-year-old woman was diagnosed as having ER-positive breast cancer, and was treated with primary endocrine therapy because she refused to undergo surgery under general anesthesia. The patient was treated with letrozole as the initial endocrine therapy, but was judged to have progressive disease after 11 months. During letrozole treatment, the patient could not achieve an effect greater than stable disease. Thereafter, she received toremifene treatment (40 mg/day). After three months of this treatment, the patient achieved a partial response. The response was maintained for 12 months, and the patient then underwent lumpectomy under local anesthesia. In conclusion, toremifene could be an effective preoperative primary endocrine regimen for elderly breast cancer patients.
Gan to kagaku ryoho. Cancer & chemotherapy 12/2011; 38(13):2627-9.
-
[show abstract]
[hide abstract]
ABSTRACT: We experienced a case of Luminal B recurrent breast cancer with liver and lymph node metastases achieving significant improvement by S-1 plus trastuzumab combination therapy. This patient was a 47-year-old woman. Trastuzumab monotherapy was administered after recurrence, but her condition grew worse. Thus, we started combination therapy of trastuzumab plus S-1. S-1 was administered orally at 100 mg/day every day for 4 weeks followed by a 1-week rest period as one course, and trastuzumab was then injected at 2 mg/kg every week. All metastases disappeared after two courses of the treatment, and no new malignant lesions appeared. In conclusion, combination therapy of S-1 plus trastuzumab could be effective treatment for maintaining good QOL in Luminal B recurrent breast cancer with lymph node and liver metastases.
Gan to kagaku ryoho. Cancer & chemotherapy 07/2010; 37(7):1321-3.
